WHITE PAPER
The future of EU HTA
How pharmaceutical companies can prepare for the new process
Nov 02, 2022

In 2021, the adoption of the legislation for joint European Health Technology Assessment (EU HTA) initiated a new era for HTA. The HTA Regulation (HTAR) aims to enable development of a joint perspective on clinical aspects of drugs, in vitro diagnostics (IVDs) and high-risk medical devices.

While all stakeholders agree that the pan-EU collaboration on HTA and harmonization of processes and requirements is valuable, the shift to a mandatory process is not without any pitfalls. In this paper, we outline some of the implications of pan-EU HTA of drugs and how industry should prepare by describing:

  • What does HTA mean at the EU level?
  • Key concerns about the new process
  • How to prepare for the future of EU HTA

Read our latest whitepaper to get more insights and understand how you can be better prepared for this new process.

Related solutions

Contact Us